Nebenwirkungen · Xelevia
Xelevia 25 mg film-coated tablets Xelevia 50 mg film-coated tablets Xelevia 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-117573 · Präparat HOS-094641
In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebo-treated patients. The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T17:33:00Z · SHA-256 f08aea892d6a7b9cf75b34f4b4074c9f6b71db0d601e841798224bb137a5083a · Passage 5a30eb64f37583e8f149fa29903b78b2b41654002b79ba9a30b0f66a494ddf29 · Zeichen 6110–6676 im Abschnitt